Last reviewed · How we verify
Combined dexmedetomidine-esketamine
Combined dexmedetomidine-esketamine is a Sedative-analgesic combination Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved for Perioperative sedation and analgesia.
This combination drug pairs dexmedetomidine (an alpha-2 adrenergic agonist) with esketamine (an NMDA receptor antagonist) to produce sedation and analgesia with dissociative properties.
This combination drug pairs dexmedetomidine (an alpha-2 adrenergic agonist) with esketamine (an NMDA receptor antagonist) to produce sedation and analgesia with dissociative properties. Used for Perioperative sedation and analgesia.
At a glance
| Generic name | Combined dexmedetomidine-esketamine |
|---|---|
| Sponsor | Peking University First Hospital |
| Drug class | Sedative-analgesic combination |
| Target | Alpha-2 adrenergic receptor; NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine acts as a selective alpha-2 adrenergic agonist that promotes sedation and analgesia while maintaining airway reflexes. Esketamine is an S-enantiomer of ketamine that antagonizes NMDA receptors, providing rapid-onset anesthesia and analgesia. The combination leverages synergistic sedative and analgesic effects for perioperative use.
Approved indications
- Perioperative sedation and analgesia
Common side effects
- Hypotension
- Bradycardia
- Dissociation
- Dizziness
- Nausea
Key clinical trials
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality (NA)
- Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients (PHASE4)
- Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia (PHASE4)
- Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients (PHASE4)
- Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia (PHASE4)
- The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combined dexmedetomidine-esketamine CI brief — competitive landscape report
- Combined dexmedetomidine-esketamine updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI
Frequently asked questions about Combined dexmedetomidine-esketamine
What is Combined dexmedetomidine-esketamine?
How does Combined dexmedetomidine-esketamine work?
What is Combined dexmedetomidine-esketamine used for?
Who makes Combined dexmedetomidine-esketamine?
What drug class is Combined dexmedetomidine-esketamine in?
What development phase is Combined dexmedetomidine-esketamine in?
What are the side effects of Combined dexmedetomidine-esketamine?
What does Combined dexmedetomidine-esketamine target?
Related
- Drug class: All Sedative-analgesic combination drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor; NMDA receptor
- Manufacturer: Peking University First Hospital — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Perioperative sedation and analgesia
- Compare: Combined dexmedetomidine-esketamine vs similar drugs
- Pricing: Combined dexmedetomidine-esketamine cost, discount & access